Consequences of cervical pessary for subsequent pregnancy : follow-up of randomized clinical trial (ProTWIN)

Funding Information: B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). B.W.M. reports consultancy for ObsEva and has received research funding from Guerbet, Ferring and Merck. The original ProTWIN trial was funded by ZonMW grant 200310004. We did not receive any funding for this follow‐up research.Peer reviewedPublisher PD

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

INTRODUCTION: Lupus nephritis (LN) is a severe and frequent manifestation of systemic lupus erythematosus (SLE). Its pathogenesis has not been fully elucidated but immune complexes are considered to contribute to the inflammatory pathology in LN. High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein which is secreted from different types of cells during activation and/or cell death and may act as a pro-inflammatory mediator, alone or as part of DNA-containing immune complexes in SLE. Urinary excretion of HMGB1 might reflect renal inflammatory injury. To assess whether urinary HMGB1 reflects renal inflammation we determined serum levels of HMGB1 simultaneously with its urinary levels in SLE patients with and without LN in comparison to healthy controls (HC). We also analyzed urinary HMGB1 levels in relation with clinical and serological disease activity. METHODS: The study population consisted of 69 SLE patients and 17 HC. Twenty-one patients had biopsy proven active LN, 15 patients had a history of LN without current activity, and 33 patients had non-renal SLE. Serum and urine levels of HMGB1 were both measured by western blotting. Clinical and serological parameters were assessed according to routine procedures. In 17 patients with active LN a parallel analysis was performed on the expression of HMGB1 in renal biopsies. RESULTS: Serum and urinary levels of HMGB1 were significantly increased in patients with active LN compared to patients without active LN and HC. Similarly, renal tissue of active LN patients showed strong expression of HMGB1 at cytoplasmic and extracellular sites suggesting active release of HMGB1. Serum and urinary levels in patients without active LN were also significantly higher compared to HC. Urinary HMGB1 levels correlated with SLEDAI, and showed a negative correlation with complement C3 and C4. CONCLUSION: Levels of HMGB1 in urine of SLE patients, in particular in those with active LN, are increased and correlate with SLEDAI scores. Renal tissue of LN patients shows increased release of nuclear HMGB1 compared to control renal tissue. HMGB1, although at lower levels, is, however, also present in the urine of patients without active LN. These data suggest that urinary HMGB1 might reflect both local renal inflammation as well as systemic inflammation

Visuele beperkingen bij ouderen in Nederland – risicogroepen en mogelijkheden tot interventie

Doel Het in kaart brengen van het aantal ouderen met een visuele beperking in Nederland, nu en in de toekomst. Mogelijkheden tot interventie worden aangegeven. Methode en materiaal De schattingen zijn gebaseerd op een recent onderzoek in opdracht van Stichting InZicht, ZonMw, waarin literatuur gegevens over prevalentie van blindheid en slechtziendheid en de oorzaken daarvan uit bevolkingsonderzoeken in Nederland, West Europa, de Verenigde Staten en Australië zijn gerelateerd aan de laatste demografische gegevens voor Nederland. Resultaten Van de 16,4 miljoen Nederlanders in 2008 zijn er 2,4 miljoen (14,7%) 65 jaar of ouder. Van deze laatste groep wonen 155.000 mensen in een verpleeg of verzorgingshuis, de rest woont zelfstandig. In 2008 zijn naar schatting 77.000 Nederlanders blind en 234.000 slechtziend. Van hen is 79% 65 jaar of ouder. Van de ouderen in instellingen is 20% blind (32.000) en 22% slechtziend (34.000). Bij 62% van hen is de visuele beperking te behandelen of was te voorkomen geweest (‘vermijdbaar’). Van de zelfstandig wonende ouderen is 1,2% blind (27.000) en 6,8% slechtziend (154.000). Bij 57% van hen is de aandoening vermijdbaar. Conclusie In 2008 hebben 247.000 ouderen een visuele beperking die bij 143.000 (58%) van hen te behandelen is of te voorkomen was geweest. Screening en behandeling van ouderen in instellingen lijkt aangewezen, evenals voorlichting aan en gerichte screening van zelfstandig wonende ouderen